NCT03285035

Brief Summary

Cryoablation combined with chemotherapy on the quality of life of patients with non resectable esophageal or gastroesophageal cancer.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jul 2017

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 13, 2017

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

August 28, 2017

Completed
18 days until next milestone

First Posted

Study publicly available on registry

September 15, 2017

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 13, 2020

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 13, 2021

Completed
Last Updated

October 11, 2019

Status Verified

October 1, 2019

Enrollment Period

3 years

First QC Date

August 28, 2017

Last Update Submit

October 8, 2019

Conditions

Keywords

CryotherapyPalliationDysphagia

Outcome Measures

Primary Outcomes (1)

  • Change in baseline quality of life (QOL) assessment using a modified EORTC QLQ-OES18 at 6 months compared to baseline

    6 months

Secondary Outcomes (9)

  • Change in dysphagia score using the 5 point Likert scale at 1 to 2 weeks post-procedure compared to baseline

    1 to 2 weeks

  • Number of participants with adverse events as assessed by CTCAE 4.03.

    30 days

  • Number of participants requiring alternative treatments for dysphagia palliation such as stenting, photodynamic therapy or brachytherapy and stenting

    1 year

  • Subjective Global Assessment scale of nutritonal status will be determined at baseline and approximately 3 month intervals.

    1 year

  • Tumor length in centimeters, endoscopist estimated luminal diameter and endoscopist subjective assessment of size as compared to the prior endoscopy will be determined

    1 to 12 weeks

  • +4 more secondary outcomes

Study Arms (1)

Non-operable esophageal cancer

Cryotherapy treatment

Device: Administration of questionaires to patients receiving an upper endoscopy with cryotherapy in addition to chemotherapy for esophageal cancer palliation.

Interventions

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients with non resectable esophageal cancer

You may qualify if:

  • Has esophageal or gastroesophageal cancer and will be receiving chemotherapy
  • Dysphagia score of 1, 2, 3 or 4.
  • Age ≥18 years old
  • American Society of Anesthesiologists (ASA) Physical Status Classification ≤ 4
  • Deemed not a candidate for esophageal cancer surgical resection
  • Female subjects must be either post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control (i.e., total abstinence, birth control pills, an intrauterine device (IUD), diaphragm, progesterone injections or implants, or condoms plus a spermicide) for the duration of the study

You may not qualify if:

  • Eastern Cooperative Oncology Group (ECOG) performance status greater than 2
  • Patient who received radiation treatment in the prior 8 weeks
  • Known brain metastases causing cranial nerve deficits which can cause dysphagia
  • Inability to undergo an esophagogastroduodenoscopy (EGD)
  • Pregnant or nursing
  • Surgery or anatomy where capacity of stomach is reduced making cryotherapy contraindicated
  • Patients with tracheoesophageal fistula

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Western Regional Medical Center, Inc.

Goodyear, Arizona, 85338, United States

RECRUITING

Related Publications (1)

  • Kachaamy T, Sharma N, Shah T, Mohapatra S, Pollard K, Zelt C, Jewett E, Garcia R, Munsey R, Gupta S, Rojas-DeLeon M, Gupta D, Kaul V, Pannala R, Vashi P. A prospective multicenter study to evaluate the impact of cryotherapy on dysphagia and quality of life in patients with inoperable esophageal cancer. Endoscopy. 2023 Oct;55(10):889-897. doi: 10.1055/a-2105-2177. Epub 2023 Jun 2.

Biospecimen

Retention: SAMPLES WITH DNA

Archival tissue or fresh tissue from gastrointestinal biopsies used for diagnostic purposes.

MeSH Terms

Conditions

Esophageal NeoplasmsDeglutition Disorders

Interventions

Cryotherapy

Condition Hierarchy (Ancestors)

Gastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsHead and Neck NeoplasmsDigestive System DiseasesEsophageal DiseasesGastrointestinal DiseasesPharyngeal DiseasesOtorhinolaryngologic Diseases

Intervention Hierarchy (Ancestors)

Therapeutics

Study Officials

  • Toufic Kachaamy, MD

    Western Regional Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 28, 2017

First Posted

September 15, 2017

Study Start

July 13, 2017

Primary Completion

July 13, 2020

Study Completion

January 13, 2021

Last Updated

October 11, 2019

Record last verified: 2019-10

Data Sharing

IPD Sharing
Will not share

Locations